- Terumo BCT and Charles River present data on the Finia automated fill and finish system’s application in cell and gene therapy (CGT) workflows.
Terumo BCT and Charles River Laboratories have released data showcasing the adaptability of Terumo BCT’s Finia automated fill and finish system in various cell and gene therapy (CGT) workflows. The Finia platform, designed to optimize the cooling, aliquoting, and packaging stages in cellular product manufacturing, addresses the challenges posed by the personalised nature and short shelf life of CGT products.
The data, published in Cytotherapy, highlights the successful integration of the Finia system into a Charles River T cell workflow. Finia processed a 304 mL product into 16 product bags over four consecutive runs, achieving a four-fold increase in capacity with a total process time of two hours. The study demonstrated that Finia produced accurate final volumes, minimized cell viability impact, and reduced hands-on time, while maintaining strict temperature control to protect cells from cryoprotectant exposure.
“We commend the work by both teams in demonstrating the broad applicability of Finia for both autologous and allogeneic CGT manufacturing,” stated Dr. Stuart Gibb, Head of Scientific Strategy for Cell and Gene Therapies at Terumo BCT. Dr. Alex Sargent, Director of Process Development at Charles River, echoed this sentiment, noting the potential for Finia’s automation to lower costs and accelerate the development and manufacturing of CGTs.
 Overview of outsourcing trends 
